Recent and new targets for small molecule anti-cancer agents
Tài liệu tham khảo
Sneader, 2005
Farber, 1947, The action of pteroylglutamic conjugates on man, Science, 106, 619, 10.1126/science.106.2764.619
Farber, 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid, N. Engl. J. Med., 238, 787, 10.1056/NEJM194806032382301
Dimarco, 1964, ‘Daunomycin’, a new antibiotic of the rhodomycin group, Nature, 201, 706, 10.1038/201706a0
Wall, 1966, Plant antitumor agents I. Isolation and structure of camtothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, J. Am. Chem. Soc., 88, 3, 10.1021/ja00968a057
Pommier, 2009, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem. Rev., 109, 2894, 10.1021/cr900097c
Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc., 93, 2325, 10.1021/ja00738a045
Goodman, 2001
Jordan, 2003, Tamoxifen: a most unlikely pioneering medicine, Nat Rev Drug Discov, 2, 205, 10.1038/nrd1031
Krum, 2008, Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival, EMBO J, 27, 535, 10.1038/sj.emboj.7601984
Zwart, 2007, Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha, Mol. Cancer Ther., 6, 1526, 10.1158/1535-7163.MCT-06-0750
Ghosh, 2009, Structural basis for androgen specificity and oestrogen synthesis in human aromatase, Nature, 457, 219, 10.1038/nature07614
Fleshner, 2007, Prostate cancer prevention: past, present, and future, Cancer, 110, 1889, 10.1002/cncr.23009
Hanks, 1995, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification, FASEB J., 9, 576, 10.1096/fasebj.9.8.7768349
Kuijl, 2007, Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1, Nature, 450, 725, 10.1038/nature06345
Reuveni, 2002, Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design, Biochemistry, 41, 10304, 10.1021/bi0202530
Quintas-Cardama, 2007, Flying under the radar: the new wave of BCR–ABL inhibitors, Nat. Rev. Drug Discov., 6, 834, 10.1038/nrd2324
Tanaka, 2008, Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation, Expert Rev. Anticancer Ther., 8, 1387, 10.1586/14737140.8.9.1387
Heinrich, 2002, Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies, J. Clin. Oncol., 20, 1692, 10.1200/JCO.20.6.1692
Gray, 1998, Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN, Br. J. Cancer, 78, 1296, 10.1038/bjc.1998.674
Hannak, 2001, Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans, J. Cell Biol., 155, 1109, 10.1083/jcb.200108051
Giet, 2001, Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis, J. Cell Biol., 152, 669, 10.1083/jcb.152.4.669
Hardwicke, 2009, GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models, Mol. Cancer Ther., 8, 1808, 10.1158/1535-7163.MCT-09-0041
Senger, 1993, Vascular permeability factor (VPF, VEGF) in tumor biology, Cancer Metastasis Rev., 12, 303, 10.1007/BF00665960
Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938
Stephens, 2004, Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature, 431, 525, 10.1038/431525b
Kalikaki, 2008, Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC, Br. J. Cancer, 99, 923, 10.1038/sj.bjc.6604629
Zhang, 1998, Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties, Oncogene, 16, 2855, 10.1038/sj.onc.1201813
Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma, N. Engl. J. Med., 348, 2609, 10.1056/NEJMoa030288
Amir, 2002, The NEDD8 pathway is essential for SCF(beta-TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105, J. Biol. Chem., 277, 23253, 10.1074/jbc.M200967200
Soucy, 2009, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer, Nature, 458, 732, 10.1038/nature07884
Garg, 2002, Nuclear transcription factor-kappaB as a target for cancer drug development, Leukemia, 16, 1053, 10.1038/sj.leu.2402482
Zhou, 2009, Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047), J. Med. Chem., 52, 3028, 10.1021/jm801329v
Ray, 1994, The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis, Eur. Respir. J., 7, 2062, 10.1183/09031936.94.07112062
Fingleton, 2003, Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects, Expert Opin. Ther. Targets, 7, 385, 10.1517/14728222.7.3.385
Shih Ie, 2007, Notch signaling, gamma-secretase inhibitors, and cancer therapy, Cancer Res., 67, 1879, 10.1158/0008-5472.CAN-06-3958
Dunn, 2005, The Ras–MAPK signal transduction pathway, cancer and chromatin remodeling, Biochem. Cell Biol., 83, 1, 10.1139/o04-121
Njoroge, 1998, (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent, J. Med. Chem., 41, 4890, 10.1021/jm980462b
Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N. Engl. J. Med., 361, 123, 10.1056/NEJMoa0900212
Huang, 2009, Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling, Nature, 461, 614, 10.1038/nature08356
Barker, 2000, The Yin-Yang of TCF/beta-catenin signaling, Adv. Cancer Res., 77, 1, 10.1016/S0065-230X(08)60783-6
Guastafierro, 2008, CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery, J. Biol. Chem., 283, 21873, 10.1074/jbc.M801170200